Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Patient is between 18 and 65 years of age (inclusive) at the time of consent
• Age of onset of Chronic Migraine \<= 64 years
• Age of onset of migraine diagnosis \< 50 years
• Patient has a current diagnosis of refractory migraine
• Patient has a current diagnosis of Chronic migraine
Locations
United States
Arizona
Barrow Neurological Institute at St. Joseph's Hospital
NOT_YET_RECRUITING
Phoenix
California
John Muir Physician Network Clin. Research Center
NOT_YET_RECRUITING
Walnut Creek
Connecticut
Hartford Hospital
RECRUITING
Hartford
New York
University of Buffalo Medical Center
NOT_YET_RECRUITING
Buffalo
Mount Sinai
RECRUITING
New York
Stony Brook University Medical Center
RECRUITING
Stony Brook
Pennsylvania
Thomas Jefferson University Hospital
RECRUITING
Philadelphia
Tennessee
Semmes Murphey Foundation
RECRUITING
Memphis
West Virginia
West Virginia University
RECRUITING
Morgantown
Contact Information
Primary
Study Contact
RA-MIGRAINECNV202302@ITS.JNJ.com
Time Frame
Start Date: 2025-04-23
Estimated Completion Date: 2029-07-31
Participants
Target number of participants: 70
Related Therapeutic Areas
Sponsors
Leads: Cerenovus, Part of DePuy Synthes Products, Inc.